- Home
- EDTK vs SCNX Comparison
EDTK vs SCNX Comparison
Compare EDTK & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDTK | SCNX |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Other Pharmaceuticals |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9M | 15.5M |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | EDTK | SCNX |
|---|---|---|
| Price | $0.98 | $0.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 13.3K | ★ 682.2K |
| Earning Date | 01-16-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,831,778.00 |
| Revenue This Year | N/A | $1,097.38 |
| Revenue Next Year | N/A | $239.80 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 30.72 |
| 52 Week Low | $0.80 | $0.24 |
| 52 Week High | $1.18 | $2.60 |
Technical Indicators
Market Signals| Indicator | EDTK | SCNX |
|---|---|---|
| Relative Strength Index (RSI) | 55.22 | 59.89 |
| Support Level | $0.96 | $0.37 |
| Resistance Level | $1.06 | $0.48 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 56.52 | 79.35 |
Price Performance
Historical ComparisonAbout EDTK Skillful Craftsman Education Technology Limited
Skillful Craftsman Education Technology Ltd provides online education and technology services in China. The services comprises of two aspects - Online vocational training and Virtual simulation experimental training. It covers a wide range of subjects, including mechanics, electronics, auto repair and construction. Majority of its revenues are generated from the People's Republic of China.
About SCNX Scienture Holdings Inc.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.